Efficient E. coli Expression Strategies for Production of Soluble Human Crystallin ALDH3A1

Aldehyde dehydrogenase 3A1 (ALDH3A1) is a recently characterized corneal crystallin with its exact functions still being unclear. Expressing recombinant human ALDH3A1 has been difficult in Escherichia coli (E. coli) because of low solubility, yield and insufficient purity issues. In this report, we compared different E. coli expression strategies (namely the maltose binding protein; MBP- and the 6-his-tagged expression systems) under conditions of auto-induction and co-expression with E. coli’s molecular chaperones where appropriate. Thus, we aimed to screen the efficiency of these expression strategies in order to improve solubility of recombinant ALDH3A1 when expressed in E. coli. We showed that the MBP- tagged expression in combination with lower-temperature culture conditions resulted in active soluble recombinant ALDH3A1. Expression of the fused 6-his tagged-ALDH3A1 protein resulted in poor solubility and neither lowering temperature culture conditions nor the auto-induction strategy improved its solubility. Furthermore, higher yield of soluble, active native form of 6-his tagged-ALDH3A1 was facilitated through co-expression of the two groups of E. coli’s molecular chaperones, GroES/GroEL and DnaK/DnaJ/GrpE. Convenient one step immobilized affinity chromatography methods were utilized to purify the fused ALDH3A1 hybrids. Both fusion proteins retained their biological activity and could be used directly without removing the fusion tags. Taken together, our results provide a rational option for producing sufficient amounts of soluble and active recombinant ALDH3A1 using the E. coli expression system for conducting functional studies towards elucidating the biological role(s) of this interesting corneal crystallin.     

人白细胞介素－3在大肠杆菌中的高效表达

人白细胞介素－３（ｈｕｍａｎＩｎｔｅｒｌｅｕｋｉｎ３,ｈＩＬ－３）是一种造血前体细胞早期分化的关键调节因子。用ＰＣＲ方法从人Ｔ淋巴细胞ｃＤＮＡ文库中扩增出０．４４ｋｂ的ＤＮＡ片段,并克隆入ｐＵＣ１９载体中。经ＤＮＡ序列测定,确定０．４４ｋｂ的ＰＣＲ产物合完整的编码人白细胞介素－３成熟蛋白ｃＤＮＡ序列,并在信号肽与成熟蛋白编码序列之间通过突变引入了限制性内切酶位点和ＡＴＧ起始密码。构建的ＰＬ启动子控制下的ｈＩＬ－３ｃＤＮＡ表达质粒,转入大肠杆菌Ｔａｐ１０６,经４２℃热诱导,获得ｈＩＬ－３的表达产物。ＳＤＳ－ＰＡＧＥ电泳显示表达产物为１５ｋｄ,约占细菌总蛋白的１５％。表达产物经ＥＬＩＳＡ和Ｗｅｓｔｅｒｎ－ｂｌｏｔ验证。ｈＩＬ－３表达产物在细胞内形成包涵体,纯化包涵体,使产物纯度提高到７０．８％,产物复性后,能明显促进ｈＩＬ－３依赖细胞株生长,具有明显的生物活性。产物转移到ＰＶＤＦ膜后进行Ｎ端序列分析,Ｎ端１６个氨基酸正确。     

Lactose-induced Production of Human Soluble B Lymphocyte Stimulator (hsBLyS) in E. coli with Different Culture Strategies

Over-production of human soluble B lymphocyte stimulator (hsBLyS) was carried out with four different fed-batch culture strategies using lactose as inducer, instead of IPTG, in a fed-batch culture of Escherichia coli. As lactose acted as both inducer and carbon source, the best and simplest culture strategy was direct feeding of lactose after batch culture, thereby giving hsBLyS at 3.7 g l⁻¹ and a productivity of 0.11 g l⁻¹ h⁻¹. Revisions requested 1 September 2005 and 11 November 2005; Revisions received 7 November 2005 and 4 January 2006     

人内皮抑素基因的克隆以及在大肠杆菌中的可溶性表达研究

用PCR的方法从人胎肝cDNA文库中得到人内皮抑素基因 ,克隆测序正确后连接到硫氧还蛋白融合表达载体上 ,转化大肠杆菌BL2 1 (DE3)得到表达人内皮抑素的工程菌。用IPTG诱导表达 ,表达量达到全菌蛋白的 64%。经分析硫氧还蛋白可以辅助内皮抑素可溶性表达 ,表达的融合蛋白保持了天然蛋白的免疫学特性。而且表面带有多聚组氨酸的突变的硫氧还蛋白还简化了蛋白纯化的步骤 ,使融合蛋白可以通过固相金属螯和层析 (IMAC)的方法纯化。纯化后的融合蛋白经IgA蛋白酶的切割可得到大小正确的重组人内皮抑素 ,用此方法获得的重组人内皮抑素可以在CAM试验中抑制新生血管的形成。高效可溶型表达内皮抑素的工程菌的构建成功 ,为内皮抑素的生产应用打下了良好的基础。     

重组人ZP3蛋白在大肠杆菌中的高效表达

目的:用基因工程方法制备重组人ZP3蛋白。方法:以全长人ZP3 cDNA片段为模板,通过PCR扩增出编码人ZP3蛋白不同肽段的cDNA片段,然后将这些cDNA片段分别插入到表达载体pET-19b的NcoⅠ-BamHⅠ或NdeⅠ-BamHⅠ位点内,共构建成6种人ZP3蛋白非融合表达质粒(pEZP3-1~pEZP3-6)和3种人ZP3蛋白融合表达质粒(pEZP3-7~pEZP3-9)。将这9种表达质粒分别转化大肠杆菌Rosetta2(DE3)感受态细胞并选择出Apr转化子,将Apr转化子接种到NZCYM培养基中(含AP 100μg/mL),在35~37℃振荡培养到对数生长期,加入IPTG至1.0~1.5mmol/L浓度诱导培养3h,离心收集细胞进行SDS-PAGE电泳检测和Western Blot杂交分析。结果:这9种人ZP3蛋白表达质粒在大肠杆菌Rosetta2(DE3)中得到高效表达,目的蛋白占总细胞蛋白的10~25%,表达产物均以包涵体形式存在。结论:成功构建了重组人ZP3蛋白原核表达系统,为进一步研究和应用人ZP3蛋白打下了基础。     

Production of Bioactive Soluble Interleukin-15 in Complex with Interleukin-15 Receptor Alpha from a Conditionally-Replicating Oncolytic HSV-1

Oncolytic type-1 herpes simplex viruses (oHSVs) lacking the γ₁34.5 neurovirulence gene are being evaluated for treatment of a variety of malignancies. oHSVs replicate within and directly kill permissive cancer cells. To augment their anti-tumor activity, oHSVs have been engineered to express immunostimulatory molecules, including cytokines, to elicit tumor-specific immune responses. Interleukin-15 (IL-15) holds potential as an immunotherapeutic cytokine because it has been demonstrated to promote both natural killer (NK) cell-mediated and CD8⁺ T cell-mediated cytotoxicity against cancer cells. The purpose of these studies was to engineer an oHSV producing bioactive IL-15. Two oHSVs were constructed encoding murine (m)IL-15 alone (J100) or with the mIL-15 receptor α (mIL-15Rα, J100D) to determine whether co-expression of these proteins is required for production of bioactive mIL-15 from oHSV. The following were demonstrated: i) both oHSVs retain replication competence and cytotoxicity in permissive tumor cell lines. ii) Enhanced production of mIL-15 was detected in cell lysates of neuro-2a cells following J100D infection as compared to J100 infection, suggesting that mIL-15Rα improved mIL-15 production. iii) Soluble mIL-15 in complex with mIL-15Rα was detected in supernates from J100D-infected, but not J100-infected, neuro-2a, GL261, and CT-2A cells. These cell lines vary in permissiveness to oHSV replication and cytotoxicity, demonstrating soluble mIL-15/IL-15Rα complex production from J100D was independent of direct oHSV effects. iv) The soluble mIL-15/IL-15Rα complex produced by J100D was bioactive, stimulating NK cells to proliferate and reduce the viability of syngeneic GL261 and CT-2A cells. v) J100 and J100D were aneurovirulent inasmuch as no neuropathologic effects were documented following direct inoculation into brains of CBA/J mice at up to 1x10⁷ plaque forming units. The production of mIL-15/mIL-15Rα from multiple tumor lines, as well as the lack of neurovirulence, renders J100D suitable for investigating the combined effects of oHSV and mIL-15/IL-15Rα in various cancer models.     

重组人脑源性神经营养因子在大肠杆菌中的可溶性表达及纯化

按照人脑源性神经营养因子(hBDNF)基因成熟肽编码序列设计合成引物,从人基因组DNA中扩增出360bp的片段,插入到改构载体pTIG-trx上,获得了pTIG-trx—BDNF原核表达重组质粒,限制性酶切分析和DNA序列测定均证实该克隆插入片段为hBDNF基因成熟肽编码序列。将该重组质粒转化大肠杆菌BL21(DE3),经IPTG诱导表达,在大肠杆菌表达系统中获得了高效可溶表达,并对表达产物进行了分离纯化,得到纯度大于83％的样品,Western杂交证实该蛋白具有hBDNF抗原活性。     

人可溶性白介素4受体(sIL4R)在大肠杆菌中的表达和纯化

白细胞介素 4 (IL 4 )作为一种多功能的细胞因子在哮喘等变态性炎症反应中具有关键作用 .IL 4通过结合细胞表面的白介素 4受体 (IL 4R)发挥其生物学效应 .sIL 4R缺少跨膜和胞内结构域 ,结合IL 4后不能产生信号传递介导IL 4的生物学活性 ,但sIL 4R与IL 4结合的高度特异性和极高的亲和力使它非常适合作为理想的IL 4拮抗剂 ,应用于哮喘等疾病治疗 .采用RT PCR方法 ,以人单核细胞总RNA为模板扩增得到编码sIL 4R的基因片段 ,经测序确证后插入大肠杆菌高效表达质粒pBV2 2 0 ,得到重组质粒pBV2 2 0 sIL 4R ,重组质粒转化E .coliDH5α .重组菌经温度诱导后超声破碎得到包涵体 ,经SuperdexHR75分子筛柱和DEAE SepharoseFastFlow离子交换柱进行纯化 ,HPLC检测表明纯度达到 90 % .N端测序证明 ,重组sIL 4R与天然sIL 4RN端序列完全一致 .Western印迹、配基结合印迹对重组sIL 4R进行鉴定 .结果表明 ,重组sIL 4R具有结合IL 4的生物学活性     

重组人白细胞介素—2制备工艺的研究

本文对大肠杆菌表达的重组人白细胞介素-2进行了制备工艺的研究。用4mol／L脲溶解可溶性细菌蛋白后可使rIL—2包涵体纯度达70％;在变性条件下进行凝胶过滤并收集rlL－2主峰纯度可达90％;利用Cu2 氧化复性;最后用反相HPLC纯化,得到高度均一,纯度高达98％,比活达到8．0×106U／mg蛋白,且无热源,无残留DNA的rIL—2;每次反相色谱分离过程可获得400mg左右的rIL－2,得率约25％。     

A组人轮状病毒NSP3基因的克隆及其在大肠杆菌中的表达

目的:获得轮状病毒NSP3基因的表达产物及其抗血清。方法:将TB-Chen株轮状病毒NSP3基因插入质粒pETL,构建重组表达质粒pET-NSP3,并转化大肠杆菌BL21(DE3)表达重组蛋白NSP3;用凝胶分离回收的方法纯化该蛋白,免疫豚鼠制备该蛋白的抗血清。结果:构建了重组表达质粒pET-NSP3,并在大肠杆菌中高效表达了重组蛋白NSP3,目的蛋白表达量占菌体总蛋白量的28.6%;有效地纯化了目的蛋白并制备了该蛋白的抗血清,Western印迹表明该抗血清能与重组蛋白NSP3发生特异性免疫反应。结论:通过质粒pETL能高效表达轮状病毒NSP3蛋白,该重组蛋白具有较好的免疫反应性,为进一步研究其结构、功能及免疫学性质奠定了基础。     

Intein 介导的重组人AR DBD的原核可溶性表达、纯化及活性鉴定

雄激素受体通过DNA结合域与效应元件结合发挥作用,在以往的研究中多采用与GST或Protein A融合的方式对雄激素受体的DNA结合域(AR DBD)进行重组表达,但获得无融合标签的纯AR DBD的操作非常繁琐。现借助内含肽介导的自剪切作用经一步亲和层析得到纯度较高的无融合标签的AR DBD,以利于对其性质和功能的研究。通过PCR方法扩增了编码人雄激素受体520~644位氨基酸的核苷酸序列,将该序列克隆入pTWIN1融合表达载体,转化大肠杆菌BL21(DE3)后对诱导温度及IPTG浓度进行优化,重组蛋白几乎全部可溶表达。将可溶性部分吸附到几丁质亲和层析柱上,通过pH诱导的内含肽自剪切作用释放出不含融合标签的重组人AR DBD蛋白,凝胶阻滞分析证明该蛋白只特异性结合保守的雄激素响应元件(ARE),具备正常的生物学活性。     

丙型肝炎病毒包膜蛋白E2可溶性单链可变区抗体在大肠杆菌中的表达

利用分子生物学技术,构建表达丙型肝炎病毒(HCV)包膜蛋白E2的人源单链可变区抗体(ScFv)的原核表达载体,并在大肠杆菌JM109中表达可溶性的HCV-E2-ScFv.以重组的HCVE2蛋白为包被抗原,利用噬菌体抗体库的表面展示技术,筛选到含有HCV-E2-ScFv基因的噬菌体克隆,从噬菌体抗体阳性克隆中提取质粒,经Ncol/NotI酶切鉴定后,该ScFv基因由750bp组成,将其亚克隆到pCANTAB5E载体中,转化大肠杆菌JM109,提取质粒进行DNA序列测定,符合ScFv的基因结构特点.IPTG诱导转化的大肠杆菌JM109,在其培养上清中获得了可溶性HCVE2单链可变区抗体的表达.酶联免疫吸附法(ELISA)证实表达的HCV-E2-ScFv具有与重组HCVE2蛋白的反应活性和特异性,对转化的JM109大肠杆菌上清中表述的HCV-E2-ScFv进行聚丙烯酰胺凝胶电泳(PAGE),证实表达的HCV-E2-ScFv的分子量为28kD.为应用HCV-E2-ScFv进行肝组织免疫组织化学和细胞内免疫基因治疗研究奠定了基础.     

丙型肝炎病毒包膜蛋白E2可溶性单链可变区抗体在大肠杆菌中的表达

利用分子生物学技术,构建表达丙型肝炎病毒（HCV）包膜蛋白E2的人源单链可变区抗体（ScFv)的原核表达载体,并在大肠杆菌JM109中表达可溶性的HCV－E2－ScFv。以重组的HCV E2蛋白为包被抗原,利用噬菌体抗体库的表面展示技术,筛选含有HCV－E2－ScFv基因的噬菌体克隆,从噬菌体抗体阳性克隆中提取质粒,经Ncol/NotⅠ酶切鉴定后,该ScFv基因由750bp组成,将菜亚克隆到pCANTAB5E载体中,转化大肠杆菌JM109,在其培养上清中获得了可溶性HCV E2单链可变区抗体的表达。酶联免疫吸附法（ELISA）证实表达的HCV－E2－ScFv进行聚丙烯酰胺凝胶电泳（PAGE）,证实表达的HCV－E2－ScFv的分子量为28KD,为应用HCV－E2－ScFv进行肝组织免疫组织化学和细胞内免疫基因治疗研究奠定了基础。     

中国人γ－干扰素cDNA在大肠杆菌中的高效表达

应用RT-PCR技术从中国人淋巴细胞mRNA反转录产物中克隆了IFN-γcDNA,序列分析证实了分子进化规律对IFN-γcDNA序列存在多态性的推论.在此基础上应用DNA重组技术,将去信号肽中国人IFN-γcDNA克隆到原核表达质粒pBV220 P_RP_L启动子下游,转化大肠杆菌DH5α,通过温度诱导表达,成功地在大肠杆菌中稳定、高效地表达了中国人IFN-γcDNA,其表达水平占全菌可溶性总蛋白的44.4%,初步复性后生物学活性测定结果表明γ-IFN表达量为0.45×10⁷～2.34×10⁷单位/L.     

GST-IL-21融合蛋白在大肠杆菌中的表达及其活性测定

目的:克隆人白细胞介素21(IL-21)编码区的cDNA,在大肠杆菌中得以表达,并检测其促进人外周血单核细胞(PBMC)增殖的生物学活性。方法:利用基因工程技术,以植物血凝素(PHA)刺激的人扁桃体细胞cDNA文库为模板,经PCR扩增获得IL-21的编码基因,并将其重组于表达载体pGEX4T-2中,转化大肠杆菌DH5α进行诱导表达,纯化得到GST-IL-21重组融合蛋白;MTT法检测其对促进PBMC增殖的功能。结果:获得了IL-21编码区的cDNA克隆;SDS-PAGE显示经IPTG诱导表达的该融合蛋白相对分子质量为41000;纯化后的GST-IL-21融合蛋白在体外具有显著的促进PBMC增殖的作用。结论:GST-IL-21融合蛋白在原核表达系统中可以有效表达,并具有较好的生物学活性。     

人促甲状腺素受体膜外区蛋白在原核系统表达及其生物活性鉴定

为研究重组人促甲状腺素受体 (hTSHR)膜外区表达产物及其生物活性与免疫活性 ,将hT SHR膜外区编码基因 (编码第 3～ 4 2 0位氨基酸 )重组到表达型质粒pGEX 4T 3上 ,测序结果表明序列正确 ,未改变读码框架 .然后转入E .coliAd4 94进行诱导表达 .纯化后的表达产物经SDS PAGE、Western印迹及放射受体法分别检测其分子量、免疫活性和生物活性 .重组TSHR3～ 4 2 0 膜外区蛋白 (简称TSHR3～ 4 2 0 )产率为 15 9～ 2 0 2 μg L培养基 ,分子量为 4 8.9kD ;融合蛋白 (简称GST TSHR3～ 4 2 0 )分子量为 75 .4kD .两种表达产物都可与TSHRAb反应 ;TSHR3～ 4 2 0 可与12 5I TSH结合 .     

An Improved Strategy for Efficient Expression and Purification of Soluble HIV-1 Tat Protein in E.coli

Although the endogenous function of Tat has been elucidated in the past twenty years, the study of its exogenous activity has been hampered due to the difficulty of large scale preparation of the active Tat protein. To express the full-length Tat protein in E.coli, the tat gene was cloned from an HIV infected patient by overlapping PCR. Rare codon usage analysis showed that rare E.coli codons, especially consecutive rare codons for Arg, account for 14% （14 of 101） rare E.coli codons in the tat gene. The expression of the HIV-1 tat gene was verified to be very poor in strain BL21 （DE3） due to the abundance of rare codons; however, tat gene expression was found to be very efficient in the host strain of Rosetta-gami B （DE3）, which was supplemented with six rare tRNAs for Arg, Leu, Ile and Pro. Subsequent purification revealed that the proteins are soluble and unusually, the tagged Tat can form dimers independent of cystine disulfide bonds. The purity, integrity and molecular weight of the Tat protein were demonstrated by MALDI-TOF mass spectrometry. Reporter gene activating assay was further confirmed by investigating the transactivation activity of the recombinant Tat protein. Our improved strategy for efficient high level expression and purification of soluble Tat protein has paved the way to fully investigate its exogenous function.     

重组刺桐胰蛋白酶抑制剂a在大肠杆菌中的表达和纯化

为了大量制备重组刺桐胰蛋白酶抑制剂a(rETIa) ,对构建的基因工程菌株E .coliBL2 1(DE3)pET2 2b mETIa进行了表达条件的优化 .用摇瓶培养 ,rETIa蛋白占菌体总蛋白 4 0 %以上 .经破碎菌体 洗涤包涵体 溶解包涵体 复性初步纯化后 ,再经二步柱层析纯化获得电泳纯的rETIa蛋白 .测定了rETIa对胰蛋白酶、胰凝乳蛋白酶、组织型纤溶酶原激活因子缺失突变体 (NTA)的抑制活性 .